Carey K. Anders, MD
Carey K. Anders, MD is a clinician-scientist and an Assistant Professor of Medicine at the University of North Carolina (UNC) School of Medicine, a member of both the UNC Lineberger Comprehensive Cancer Center and the UNC Breast Center. Dr. Anders’ research focuses on the biology of breast cancer and during her fellowship at Duke University she did research examining age-specific genomic differences in human breast carcinoma. As faculty at UNC, she has addressed brain metastases arising from breast cancer. She has served as the Principal Investigator of a Cancer and Leukemia Group B Young Investigator Award examining the activation status of important oncogenic signaling pathways in human breast carcinoma brain metastases. She serves as the PI of several multicenter, phase II studies in the setting of breast cancer brain metastases – one testing iniparib in triple negative breast cancer, the second testing mTOR inihibition in Her2-positive breast cancer, and a third evaluating the safety and efficacy of GRN1005 (a novel taxane capable of crossing the blood brain barrier). In addition, she is a co-investigator on several studies evaluating the efficacy and long-term effects of radiation therapy for patients with brain metastases. In parallel and in the laboratory, she has developed several intracranial breast cancer tumor models to test novel therapies, including small molecule and nanoparticle chemotherapeutics. She is a member of the Translational Breast Cancer Research Consortium and the NCI-Breast Cancer Brain Metastases Working Group. She is the recipient of several internal and external grants to fund her research including a NIH/NCI K23 Career Development Award a Damon Runyon Cancer Foundation Clinical Investigator Award. Her overall career goal is to develop novel, therapeutic strategies to improve survival and quality of life for patients with breast cancer brain metastases.
- Breakthroughs in Neoadjuvant Therapies
- Adding Carboplatin to Chemotherapy May Improve Treatment Response in Triple-Negative Breast Cancer
- MARIANNE Trial Shows T-DM1 Works About As Well As Standard First Treatment for HER2-Positive Metastatic Breast Cancer
- Left Behind: Key Findings From Living Beyond Breast Cancer’s National Needs Assessment of Women With Triple-Negative Breast Cancer